Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1430474

Case report: Short-course hypofractionated radiation therapy combined with immune checkpoint inhibitors for the treatment of advanced ovarian mucinous cystadenocarcinoma

Provisionally accepted
Xinan Wan Xinan Wan *Mingxing Fang Mingxing Fang Le Yuan Le Yuan Hang Zhang Hang Zhang Dan Wang Dan Wang
  • Second People's Hospital of Wuhu, Wuhu, China

The final, formatted version of the article will be published soon.

    Background: Ovarian mucinous cystadenocarcinoma is a rare subtype of ovarian epithelial carcinoma that is resistant to platinum-based chemotherapy and has a poor prognosis, and there is no standard treatment plan for patients for whom multiline treatment has failed. Case presentation: We report a patient with ovarian mucinous cystadenocarcinoma with FIGO stage ⅣB disease who was sequentially treated with paclitaxel liposomes+carboplatin, 5-Fu+CF+oxaliplatin, capecitabine+oxaliplatin, bevacizumab+FOLFOX4, S-1, and bevacizumab+oxaliplatin+raltitrexed chemotherapy. After the progression of the disease, a combination of short-course hypofractionated radiation therapy and immune checkpoint inhibitors was used. The radiotherapy target area was the metastatic lymph nodes in the right posterior part of the hepatic artery, with a radiation dose of 30 Gy/10 F. Camrelizumab, an immune checkpoint inhibitor, was administered intravenously every three weeks at a dose of 200 mg each time. The therapeutic effect was significant, with CA125 levels within the normal range. Metastatic lymph nodes disappeared from the abdominal cavity. The therapeutic effect achieved a complete response (CR). Currently, CA125 levels are within the normal range, and abdominal CT reveals no tumor recurrence or metastasis. The duration of response (DoR) reached over four years. Conclusion: Ovarian mucinous cystadenocarcinoma is a rare tumor with poor treatment efficacy and poor prognosis. Short-course hypofractionated radiation therapy combined with PD-1 inhibitors may be an effective and safe treatment strategy.

    Keywords: Ovarian mucinous cystadenocarcinoma, Hypofractionated radiation therapy, PD-1 inhibitors, case report, multiple-line treatments

    Received: 10 May 2024; Accepted: 03 Jan 2025.

    Copyright: © 2025 Wan, Fang, Yuan, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xinan Wan, Second People's Hospital of Wuhu, Wuhu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.